: Currently holds a unanimous Strong Buy rating from top analysts. Bank of America analysts point to a price target of $42 , representing approximately 37% upside, supported by a robust generics pipeline and upcoming FDA catalysts.
Projected EPS growth of 313% with a low forward P/E of 6.13. 🛡️ Defensive & Value Strong Buys new strong buy stocks
: Recently upgraded to Outperform by Bernstein with a $358 target . The removal of regulatory "overhangs" has led to a consensus Strong Buy rating from 13 different analysts. 📊 Quantitative "Strong Buy" Additions (Zacks Rank #1) : Currently holds a unanimous Strong Buy rating
: Currently rated as a 5-star (undervalued) stock by Morningstar with a "Wide Economic Moat". 🛡️ Defensive & Value Strong Buys : Recently
: Labeled a "biotech breakout" by Citigroup with a maximum 1-year forecast of $242 , implying a potential 89% upside .
: Recently joined the 5-star undervaluation list, seen as significantly underpriced relative to its long-term potential in the housing market.